Chromosomal translocation engineering to recapitulate primary events of human cancer

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 70, Issue , 2005, Pages 275-282

  Forster, A ^a   Pannell, R ^a   Drynan, L ^a   Cano, F ^a   Chan, N ^a   Codrington, R ^a   Daser, A ^a   Lobato, N ^a   Metzler, M ^a   Nam, C H ^a   Rodriguez, S ^a   Tanaka, T ^a   Rabbitts, T ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MIXED LINEAGE LEUKEMIA PROTEIN; RNA BINDING PROTEIN EWS; CARRIER PROTEIN; COMPLEMENTARY DNA; CRE RECOMBINASE;

CANCER; CANCER THERAPY; CHROMOSOME TRANSLOCATION; CONFERENCE PAPER; EPITHELIUM TUMOR; FUSION GENE; GENE CASSETTE; GENE TARGETING; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; INTRON; LEUKEMIA; LOXP SITE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; ARTICLE; BURKITT LYMPHOMA; CELL FATE; DNA STRUCTURE; GENE REARRANGEMENT; HOMOLOGOUS RECOMBINATION; HUMAN; MALIGNANT NEOPLASM; ONCOGENE C MYC; RECIPROCAL CHROMOSOME TRANSLOCATION; SIGNAL TRANSDUCTION;

ANIMALS; CHROMOSOMES, HUMAN; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; INVERSION, CHROMOSOME; MICE; MICE, MUTANT STRAINS; MODELS, GENETIC; NEOPLASMS; RECOMBINATION, GENETIC; TRANSLOCATION, GENETIC;

EID: 33746463949     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2005.70.008     Document Type: Conference Paper

References (22)

1. Boveri T. 1914. Zur Frage der Entstehung Maligner Tumoren. Gustav Fischer, Germany.
2. Cleary M.L. 1991. Oncogenic conversion of transcription factors by chromosomal translocations. Cell 66: 619.
3. Codrington R., Pannell R., Forster A., Drynan L.F., Daser A., Lobato M.N., Metzler M., and Rabbitts T.H. 2005. The Ews-ERG fusion protein can initiate neoplasia from lineage committed haematopoietic cells. Publ. Lib. Sci. Biol. 3: 242.
4. Collins E.C., Pannell R., Simpson E.M., Forster A., and Rabbitts T.H. 2000. Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development. EMBO Rep. 1: 127.
5. Corral J., Lavenir I., Impey H., Warren A.J., Forster A., Larson T.A., Bell S., McKenzie A.N.J., King G., and Rabbitts T.H. 1996. An Mll-Af9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes. Cell 85: 853.
6. Dobson C.L., Warren A.J., Pannell R., Forster A., Lavenir I., Corral J., Smith A.J.H., and Rabbitts T.H. 1999. The Mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J. 18: 3564.
7. Forster A., Pannell R., Drynan L.F., McCormack M., Collins E.C., Daser A., and Rabbitts T.H. 2003. Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell 3: 449.
8. Forster A., Pannell R., Drynan L.F., Codrington R., Daser A., Metzler M., Lobato M.N., and Rabbitts T.H. 2005. The invertor knock-in conditional chromosomal translocation mimic. Nat. Methods 2: 27.
9. Hanahan D. and Weinberg R.A. 2000. The hallmarks of cancer. Cell 100: 57.
10. Hoess R.H., Ziese M., and Sternberg N. 1982. P1 site-specific recombination: Nucleotide sequence of the recombining sites. Proc. Natl. Acad. Sci. 79: 3398.
11. Kogan S.C., Ward J.M., Anver M.R., Berman J.J., Brayton C., Cardiff R.D., Carter J.S., de Coronado S., Downing J.R., Fredrickson T.N., Haines D.C., Harris A.W., Harris N.L., Hiai H., Jaffe E.S., MacLennan I.C., Pandolfi P.P., Pattengale P.K., Perkins A.S., Simpson R.M., Tuttle M.S., Wong J.F., and Morse H.C. 2002. Bethesda proposals for classification of non-lymphoid hematopoietic neoplasms in mice. Blood 100: 238.
12. McCormack M.P., Forster A., Drynan L.F., Pannell R., and Rabbitts T.H. 2003. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. Mol. Cell. Biol. 23: 9003.
13. Rabbitts T.H. 1991. Translocations, master genes, and differences between the origins of acute and chronic leukemias. Cell 67: 641.
14. _. 1994. Chromosomal translocations in human cancer. Nature 372: 143.
15. Rabbitts T.H. and Stocks M.R. 2003. Chromosomal translocation products engender novel intracellular therapeutic technologies. Nat. Med. 9: 383.
16. Ramirez-Solis R., Liu P., and Bradley A. 1995. Chromosome engineering in mice. Nature 378: 720.
17. Smith A.J.H., De Sousa M.A., Kwabi-Addo B., Heppell-Parton A., Impey H., and Rabbitts P.H. 1995. A site-directed chromosomal translocation induced in embryonic stem cells by Cre-loxP recombination. Nat. Genet. 9: 376.
18. Tanaka T. and Rabbitts T.H. 2003. Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation. EMBO J. 22: 1025.
19. Tanaka T., Lobato M.N., and Rabbitts T.H. 2003. Single domain intracellular antibodies: A minimal fragment for direct in vivo selection of antigen-specific intrabodies. J. Mol. Biol. 331: 1109.
20. Tse E., Lobato M.N., Forster A., Tanaka T., Chung G.T.Y., and Rabbitts T.H. 2002. Intracellular antibody capture technology: Application to selection of single chain Fv recognising the BCR-ABL oncogenic protein. J. Mol. Biol. 317: 85.
21. van Deursen J., Fornerod M., van Rees B., and Grosveld G. 1995. Cre-mediated site-specific translocation between non-homologous mouse chromosomes. Proc. Natl. Acad. Sci. 92: 7376.
22. Yu Y. and Bradley A. 2001. Engineering chromosomal rearrangements in mice. Nat. Rev. Genet. 2: 780.